Aeterna Zentaris Inc falls to net loss of USD6.6m for Q3 2012 

Aeterna Zentaris Inc falls to net loss of USD6.6m for Q3 2012

Nov 14, 2012 (Menafn - M2 EQUITYBITES via COMTEX) --Oncology company Aeterna Zentaris Inc AEZS stated on Tuesday its net loss of USD6.6m, USD0.35 per basic and diluted share, for the third quarter ended 30 September 2012.

Compared with a net income of USD1.1m, USD0.07 per basic and USD0.06 per diluted share, for the same quarter in 2011.

The company added that the significant increase in net loss for Q3 2012 as compared to the same period in 2011 is due largely to lower net finance income, partly compensated by lower R&D and SG&A expenses.

Revenues of USD7.1m were generated for the quarter ended 30 September 2012, down when compared to revenues of USD9.5m for the same quarter in 2011 due to lower deliveries of Cetrotide to certain customers and to the relative weakening of the euro against the US dollar.

R&D costs were recorded as USD4.3m for the quarter ended 30 September 2012, a decline when compared to USD5.7m for the same quarter in 2011 due to lower third-party costs associated with the development of perifosine and AEZS108, combined with the weakening of the euro against the US dollar.

Comments on this story may be sent to info@m2.com

(C)1994-2012 M2 COMMUNICATIONS http://www.m2.com